A5083720011- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Renal cell carcinoma treatment
- RNA modifications and cancer
- Single-cell and spatial transcriptomics
- Molecular Biology Techniques and Applications
- Lung Cancer Treatments and Mutations
- Pelvic floor disorders treatments
- Ferroptosis and cancer prognosis
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- Economic and Financial Impacts of Cancer
- Cancer-related molecular mechanisms research
- Genetic factors in colorectal cancer
- Cytokine Signaling Pathways and Interactions
- Hernia repair and management
- Multiple and Secondary Primary Cancers
- Prostate Cancer Treatment and Research
- Biomedical Ethics and Regulation
- Toxin Mechanisms and Immunotoxins
- Cancer Mechanisms and Therapy
- Urinary Tract Infections Management
University of Turku
2012-2025
Turku University Hospital
2021-2025
Åbo Akademi University
2012
Turku Centre for Biotechnology
2012
Abstract Chemotherapy resistance is a major contributor of cancer-related deaths. Resistance can either be acquired during treatments or pre-exist at the time diagnosis. Previous studies on high-grade serous carcinoma (HGSC) have shown contradictory findings role genetic causes explaining emergence chemotherapy relapses, for example selection resistant clones chemotherapy. HGSC often diagnosed an advanced stage, showing multiple genetically heterogeneous present before therapeutic...
The differentiation of human primary T helper 1 (Th1) cells from naïve precursor is regulated by a complex, interrelated signaling network. identification factors regulating the early steps Th1 cell polarization can provide important insight in development therapeutics for many inflammatory and autoimmune diseases. serine/threonine-specific proviral integration site Moloney murine leukemia virus (PIM) kinases PIM1 PIM2 have been implicated cytokine-dependent proliferation survival...
Urinary incontinence (UI) during pregnancy is a common health problem. Vaginal delivery in particular affects the pelvic floor and increases risk of dysfunctions. This prospective cohort study was conducted to investigate incidence UI three months postpartum determine factors underlying UI.In total, 547 volunteer women were recruited from maternity clinic tertiary hospital. The participants filled out questionnaire twice, one second trimester other after delivery. A multivariate logistic...
Circulating tumor DNA (ctDNA) offers a minimally-invasive alternative to study genomic changes in recurrent malignancies. With high recurrence rate, the overall survival high-grade serous ovarian carcinoma (HGSC) has remained low. Our objectives were determine whether ctDNA from plasma adequately represents HGSC, and find mutational at relapse suggesting therapy options that could alter patient outcome.We collected 152 longitudinal 92 fresh tissue samples 29 HGSC patients, sequencing...
Circulating tumor DNA (ctDNA) analysis has emerged as a promising tool for detecting and profiling longitudinal genomics changes in cancer. While copy-number alterations (CNAs) play major role cancers, treatment effect monitoring using profiles received limited attention compared to mutations. A reason this is the insensitivity of CNA real-life tumor-fraction ctDNA samples. We performed on 152 plasma samples obtained from 29 patients with high-grade serous ovarian cancer (HGSC) sequencing...
Abstract In ovarian high-grade serous carcinoma (HGSC), homologous recombination deficiency (HRD) sensitizes tumors to DNA-damaging platinum-based chemotherapy, as well poly-ADP-ribose polymerase inhibitors (PARPi), resulting in longer survival compared HR-proficient patients. Cyclin E1 (CCNE1) amplified are found about 20% of HGSC patients and associate with poorer clinical outcomes. CCNE1 amplification is mutually exclusive inactivating BRCA1/2 mutations, the best-established cause for...
Abstract Ovarian high-grade serous carcinoma (HGSC) is commonly diagnosed at an advanced stage, showing multiple genetically heterogeneous clones existing prior to therapeutic intervention. Most of the patients respond well primary therapy, but cancer relapses within few years and develops treatment resistance. Genomics changes in tumors during therapy are poorly known. Thus, we characterized subclonal their contribution resistance outcome over 150 with HGSC. We used 700 longitudinal tissue...
Abstract Circulating tumor DNA (ctDNA) is the cancer-derived fraction of extracellular fragments present in bloodstream as cell-free (cfDNA). Consequently, ctDNA harbors distinct genomic information specific to cancer from which it derives. Therefore, liquid biopsies provides a non-invasive, universally available alternative traditional biopsies. amount may provide insight into burden, its concentration typically highest during diagnosis and relapse. The non-invasive nature this method...
Abstract The evolution of tumors from diagnosis to relapse in ovarian high-grade serous carcinoma (HGSC) patients is poorly understood. Consequently, it unknown whether diagnostic samples are representative enough guide treatment directions at relapse, or acquired changes during therapy provide targets with relapses. To answer these questions and characterize tumor treatment, we used data >700 tissue plasma 200 HGSC belonging the observational, longitudinal DECIDER trial...
Ovarian high-grade serous carcinoma (HGSC) represents the deadliest gynecological malignancy, with 10-15% of patients exhibiting primary resistance to first-line chemotherapy. These primarily chemo-refractory have particularly poor survival outcomes, emphasizing urgent need for developing predictive biomarkers and novel therapeutic approaches. Here, we show that interferon type I (IFN-I) pathway activity in cancer cells is a crucial determinant chemotherapy response HGSC. Through...
Abstract Neoadjuvant chemotherapy (NACT) is the preferred treatment strategy for high-grade serous (ovarian) cancer (HGSC) patients, if optimal cytoreduction estimated unachievable at time of diagnosis. In such cases, intrinsic sensitivity to standard-of-care (platinum and taxane combination therapy) a major determinant disease progression. The DECIDER project an international effort overcome mechanisms chemo-resistance by integration clinical, imaging multi-omics data layers from...
Abstract Background Circulating tumor DNA (ctDNA) analysis has emerged as a promising tool for detecting and profiling longitudinal genomic changes in cancer. While copy-number alterations (CNAs) play major role cancers, monitoring treatment effects using profiles received limited attention compared to mutations. This is primarily due the challenge of CNA real-life tumor-fraction ctDNA samples. Method Our study aimed investigate copy number assess samples, even with low fractions, cancer...
Objective: Circulating tumor DNA (ctDNA) offers a minimally invasive alternative to study genomic changes in recurrent malignancies. With high recurrence rate, the overall survival grade serous ovarian carcinoma (HGSC) has remained low. Our objective was determine that ctDNA from plasma adequately represents HGSC. We aimed find mutational at relapse suggesting therapy options could alter patient outcome.Methods: collected 152 longitudinal and 92 fresh tissue samples 29 HGSC patients,...
<h3>Introduction/Background</h3> Ovarian high-grade serous carcinoma (HGSC) is commonly diagnosed at an advanced stage, showing multiple genetically heterogeneous clones existing prior to therapeutic intervention. <h3>Methodology</h3> Clonal composition and topology were estimated from whole-genome sequencing data 510 samples of 148 patients in the prospective, longitudinal, multiregion DECIDER study. Detected subclones followed 152 longitudinal circulating tumour DNA (ctDNA) samples, by...
<h3>Introduction/Background</h3> Neoadjuvant chemotherapy (NACT) is the preferred treatment strategy for high-grade serous (ovarian) cancer (HGSC) patients, if optimal cytoreduction estimated unachievable at time of diagnosis. In such cases, intrinsic sensitivity to standard-of-care (platinum and taxane combination therapy) a major determinant disease progression. With data from 159 NACT-treated diagnosed during years 2009–2022 enrolled in prospective DECIDER study, we sought define cellular...